Figure 1.

Key outcomes for the BUILD-2 study of bosentan versus placebo in SSc-ILD. BUILD, Bosentan in Interstitial Lung Disease in Systemic Sclerosis; DLCO, carbon dioxide diffusing capacity; EOS, end of study; FVC, forced vital capacity; ILD, interstitial lung disease; 6 MWD, 6 min walk distance; Rx, treatment; SSc, systemic sclerosis.

Matucci-Cerinic et al. Arthritis Research & Therapy 2007 9(Suppl 2):S7   doi:10.1186/ar2191